Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6908302 | 0.93 | MEN1 (0.38) | TSHRMEN1KMT2A | |
| SCHEMBL10765977 | 0.93 | MEN1 (0.38) | TSHRMEN1KMT2A | |
| SCHEMBL28323877 | 0.93 | MEN1 (0.38) | TSHRMEN1KMT2A | |
| 2-Bromoethanol SCHEMBL3055303 | 0.91 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL9661524 | 0.81 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL11818110 | 0.81 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL9879608 | 0.80 | KMT2A (0.51) | TSHRMEN1KMT2APOLB | |
| SCHEMBL8645521 | 0.80 | KMT2A (0.51) | TSHRMEN1KMT2APOLB | |
| SCHEMBL11263233 | 0.78 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL28813769 | 0.78 | MEN1 (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614050-B1 | 1,5-DIARYL-2-ALKYLPYRROLE-3-SUBSTITUTED NITRO ESTERS, SELECTIVE COX-2 INHIBITORS AND NITRIC OXIDE DONORS | Rottapharm Biotech Srl (IT) | 2016-01-20 | — | — | EP | disclosed |
| US-9162979-B2 | 1,5-Diary1-2-alkylpyrrole-3-substituted nitro esters, selective COX-2 inhibitors and nitric oxide donors | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-10-20 | — | — | US | disclosed |
| EP-2614050-A1 | 1,5-DIARYL-2-ALKYLPYRROLE-3-SUBSTITUTED NITRO ESTERS, SELECTIVE COX-2 INHIBITORS AND NITRIC OXIDE DONORS | Rottapharm S.p.A. (IT) | 2013-07-17 | — | — | EP | disclosed |
| US-20130165494-A1 | 1,5-Diaryl-2-alkylpyrrole-3-Substituted Nitro Esters, Selective COX-2 Inhibitors and Nitric Oxide Donors | ROTTAPHARM S.P.A. (IT) | 2013-06-27 | — | — | US | disclosed |
| WO-2012032479-A1 | L,5-DIARYL-2-ALKVLPVRROLE-3-SUBSTITUTED NITRO ESTERS, SELECTIVE COX-2 INHIBITORS AND NITRIC OXIDE DONORS | ROTTAPHARM S.P.A. (IT) | 2012-03-15 | — | — | WO | disclosed |
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | PALAU PHARMA, S.A. (ES) | 2010-09-02 | — | — | US | disclosed |
| EP-1907358-A2 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007000340-A2 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | disclosed |
| CN-1199960-C | Agarofuran derivatives, their preparing process, medicinal composition containing them and their medicinal usage | MEDICAL MATERIAL INST CHINESE (CN) | 2005-05-04 | — | — | CN | disclosed |
| CN-1322525-A | Dehydrogenated falcate micromelum costusic alcohol derivative as medicine for preventing or treating cerebral retrogressive lesion | INST OF PHARMACOLOGY CHINESE A (CN) | 2001-11-21 | — | — | CN | disclosed |
| CN-1254713-A | Agarofuran derivatives, their preparing process, medicinal composition containing them and their medicinal usage | MEDICAL MATERIAL INST CHINESE (CN) | 2000-05-31 | — | — | CN | disclosed |
| EP-0171251-B2 | QUINONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1992-12-23 | — | — | EP | disclosed |
| EP-0171251-A2 | Quinone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | MAPK1, MAPKAPK2, MAPK7 | TSHR 3973/4885MEN1 4549/4885KMT2A 3609/4885 |
| US-20130165494-A1 | 1,5-Diaryl-2-alkylpyrrole-3-Substituted Nitro Esters, Selective COX-2 Inhibitors and Nitric Oxide Donors | NOS3, PTGER3, PTGES3 | TSHR 903/4885MEN1 3128/4885KMT2A 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.